Programme no. 306-SY
Statins for many. How many?
Jan Håkansson*1, Halfdan Petursson*2, Hans Blomberg*3, Peter Nilsson*4
1Krokoms HC,Krokom,Sweden, 2Institutt for samfunnsmedisin,Norges Teknisk-Naturvitenskapelige Universitet,Trondheim,Norway, 3,Sibbo health center,Sibbo,Finland, 4,Institutionen för kliniska vetenskaper; VO internmedicin,Malmö,Sweden
* = Presenting author
Objectives: To scrutinize new guidelines for statin treatment and their consequences for people at risk for cardiovascular disease. Potential changes in primary health care work.
Background: Evidence for beneficial effects of statins to prevent cardiovascular disease have emerged the last decades. Recently updated guidelines broaden indications for statin treatment, particularly for primary prevention. These guidelines have large consequences for healthy people at risk for cardiovascular disease and for primary health care and are lively debated.
- The epidemiological context according to earlier and actual guidelines.
- International outlook. Similarities and differences in some updated influential guidelines
- Pros and cons with expanded statin treatment.
- Changes in risk classifications and how these can be communicated in a comprehensible way.
- Shared decision making between the medical profession, the individual and society.
- Allocation of medical resources for cardiovascular disease prevention and other public health problems.
Method: Lectures and discussion
Other considerations: -